Newman Dignan & Sheerar, Inc. Clearside Biomedical, Inc. Transaction History
Newman Dignan & Sheerar, Inc.
- $429 Million
- Q2 2025
A detailed history of Newman Dignan & Sheerar, Inc. transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Newman Dignan & Sheerar, Inc. holds 30,123 shares of CLSD stock, worth $126,215. This represents 0.01% of its overall portfolio holdings.
Number of Shares
30,123
Previous 30,123
-0.0%
Holding current value
$126,215
Previous $27,000
11.11%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding CLSD
# of Institutions
48Shares Held
11.8MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA3.36MShares$14.1 Million0.0% of portfolio
-
Act Capital Management, LLC Wayne, PA2.2MShares$9.21 Million3.43% of portfolio
-
Carmignac Gestion Paris, I01.51MShares$6.32 Million0.02% of portfolio
-
Black Rock Inc. New York, NY798KShares$3.34 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA790KShares$3.31 Million0.0% of portfolio
About Clearside Biomedical, Inc.
- Ticker CLSD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,190,700
- Market Cap $252M
- Description
- Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...